NCT05319249View on ClinicalTrials.gov

Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

NK cells

NK cells will be given as a single intravenous infusion.

DRUG

Talazoparib 1 MG [Talzenna]

Subjects will receive treatment with Talazoparib capsules 1 mg/day (4 days) with subsequent intravenous NK cell infusion.

All Listed Sponsors
lead

German Cancer Research Center

OTHER

NCT05319249 - Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter